Intra-Cellular Therapies(ITCI) - 2024 Q1 - Quarterly Results
Intra-Cellular Therapies(US:ITCI)2024-05-07 11:40Exhibit 99.1 INTRA-CELLULAR THERAPIES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS CAPLYTA Q1 2024 net product sales were $144.8 million, compared to $94.7 million for the same period in 2023, representing a 53% increase CAPLYTA's strong prescription uptake continues: Q1 2024 CAPLYTA total prescriptions increased 39%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance reiterated at $645 - $675 million Announced robust positive Phase 3 results from Study 501 evaluating lumateperone as an ...